CBD Product Manufacturing in European Union: Market Size, Businesses & Forecast 2026

The CBD product manufacturing industry in the European Union encompasses the extraction, processing, and formulation of non-psychoactive cannabidiol derived primarily from industrial hemp for use in cosmetics, wellness oils, and dietary supplements. The sector is transitioning from an unregulated niche into a highly scrutinized compliance-driven market due to changing pan-European regulatory mandates. According to the European Commission, the total agricultural area dedicated to raw industrial hemp cultivation within the EU reached 34,960 hectares in 2019, representing a critical upstream supply anchor for regional manufacturers. The industry's near-term direction is heavily dictated by ongo

Industry snapshot

Key public data points

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the CBD Product Manufacturing in European Union industry cover?

The industry involves the processing of industrial hemp (Cannabis sativa L.) to extract cannabidiol (CBD) and isolate specific cannabinoid formulations. These extracts are manufactured into sub-products including consumer oils, tinctures, topical cosmetics, and potential food ingredients. The scope is strictly bounded by legal thresholds governing psychoactive compounds, ensuring products do not cross established narcotic limits.

• •Primary inputs are limited to industrial hemp varieties registered in the EU Common Catalogue of Agricultural Plant Species.
• •The regulatory threshold for tetrahydrocannabinol (THC) in cultivated hemp was raised from 0.2% to 0.3% effective January 1, 2023, under the EU Common Agricultural Policy (CAP).
• •Finished manufactured goods are categorized into ingestible formulations (oils, capsules, isolates) and non-ingestible topicals (creams, balms, and skincare).

Who operates in the industry and how is it structured?

The European market structure is highly fragmented and characterized by a vast network of small to medium-sized enterprises (SMEs) processing locally sourced hemp alongside localized extraction hubs. Because there is no fully harmonized pan-European market execution for ingestibles, operators frequently establish multi-jurisdictional setups to handle regional variations in enforcement. Manufacturing facilities increasingly utilize advanced processing techniques to fulfill corporate transparency and quality requirements.

• •France serves as the leading supplier of raw agricultural inputs, cultivating nearly 18,000 hectares of hemp as documented by the European Commission.
• •Supercritical CO2 extraction has become the mainstream technological standard among high-purity industrial processors to avoid residual solvent contamination.
• •Operators are represented at the EU institutional level by the European Industrial Hemp Association (EIHA), which manages collective Novel Food application consortia.

What drives demand in the industry?

Demand is primarily driven by shifting consumer preferences toward plant-derived wellness alternatives, botanical skincare remedies, and natural stress-relief cosmetics. The market is also supported by agricultural diversification strategies encouraged under the European Green Deal, which frames industrial hemp as a highly sustainable crop. Additionally, commercial validation from downstream industries like mainstream cosmetics and pharmaceuticals expands the structural demand base.

• •Consumer demand is heavily concentrated in demographics seeking localized anti-inflammatory and antioxidant solutions within the personal care sector.
• •The European Commission promotes expanded hemp usage to replace fossil-fuel-intensive and carbon-heavy industrial inputs.
• •Strategic shifts toward e-commerce platforms provide manufacturers direct-to-consumer pipelines despite regional retail restrictions.

Who are the notable companies in the industry?

The competitive environment features intense competition between local botanical extractors, vertically integrated hemp producers, and diversified international life-sciences corporations. Public companies operating within the wider European cannabis and CBD supply chains face stringent capital conditions and changing asset structures. Due to strict compliance requirements, large multinationals often leverage localized subsidiaries to maintain compliant manufacturing chains across various Member States.

• •MGC Pharmaceuticals Ltd (operating as Intelligent Bio Solutions or through local European clinical operations) maintains an active footprint in European cannabinoid processing.
• •SynBiotic SE acts as a prominent consolidated holding company orchestrating hemp cultivation, extraction, and CBD product distribution across Germany and Central Europe.
• •Hemirex and similar regional industrial extractors handle large-scale primary processing of hemp stalks and flowers across Central Europe.
• •Ananda Scientific and various international life-sciences operators utilize European facilities to advance water-soluble CBD formulations for regional commercialization.

What are the recent trends and outlook?

The manufacturing outlook is heavily influenced by the legal separation between ingestible CBD and topical cosmetics. While ingestible product pipelines face persistent operational bottlenecks due to safety reviews, the CBD cosmetics sector is experiencing unrestricted growth. Manufacturers are actively shifting R&D budgets toward water-soluble formulations and standardized dosing lines to prepare for eventual market normalization.

• •CBD cosmetics avoid Novel Food restrictions by complying directly with standard EU Cosmetic Regulations, allowing rapid regional cross-border distribution.
• •Payment processing compliance and high-risk merchant underwriting rules serve as critical operational infrastructure challenges for regional manufacturers.
• •According to historic EU agricultural data, raw processing yields for hemp flowers and leaves grew from 7.5 tonnes in 2010 to 240 tonnes by 2013, demonstrating long-term industrial scaling.

How is the industry regulated?

Compliance is the core determinant of operational legality within the European Union market. All ingestible CBD products remain officially classified as Novel Foods under Regulation (EU) 2015/2283 because they lack a documented history of human consumption prior to May 1997. This classification requires manufacturers to obtain pre-market authorization from the European Food Safety Authority (EFSA) before legally placing products on consumer shelves.

• •EFSA safety evaluations for CBD ingestibles have periodically paused due to requirements for more comprehensive, long-term toxicological and clinical data.
• •The landmark 2020 Court of Justice of the European Union (CJEU) ruling in Case C-663/18 (the Kanavape case) established that CBD extracted from the whole hemp plant cannot be classified as a narcotic under EU law.
• •Individual EU Member States exercise discretionary powers to enforce national safety laws, resulting in strict bans in countries like France versus tolerant policies elsewhere.

Government, statistical and trade sources used for this Claight analysis.

• European Commission Directorate-General for Agriculture and Rural Development 2023 ·
• European Food Safety Authority (EFSA) Novel Food Status Updates 2025 ·
• USDA Foreign Agricultural Service Industrial Hemp Market Trends Report 2022 ·
• Court of Justice of the European Union (CJEU) Case C-663/18 Judgement